The Patent Cliff Is Real —What Growth-Stage Biopharma CEOs Should Do Now

The patent cliff gets talked about as a Big Pharma problem. Humira's biosimilar wave. Roche navigating the loss of exclusivity on Perjeta, Kadcyla, and Ocrevus. AbbVie pivoting its entire immunology and neuroscience franchise to replace hundreds of billions in at-risk revenue. Merck facing USD18 billion in patent-driven revenue losses over the next five years — a pressure so acute it nearly drove a USD30 billion acquisition of Revolution Medicines in January 2026. 

But if you are the CEO of a growth-stage biopharma company, the patent cliff is not their problem. It is your opportunity. And the window to position yourself for it is right now.

Here is why — and what to do about it.

The Scale of the Opportunity

The numbers are hard to overstate. Between USD 200 and USD 400 billion in branded pharmaceutical revenue will lose patent protection between 2025 and 2030 — including Keytruda (USD 25 billion), Eliquis (USD 12 billion), and Stelara (USD 10.9 billion). Nearly 70 blockbuster drugs are losing exclusivity in this window. The scale is unprecedented.

Large acquirers — under intense board pressure to replace that revenue — have already accelerated M&A activity dramatically. IQVIA confirms that M&A spend in biopharma nearly doubled in 2025, with nine acquisitions exceeding USD 10 billion — the highest concentration of mega-deals on record. ING forecasts that deal activity will continue to accelerate in 2026, driven by the patent cliff, lower interest rates, and growing appetite for obesity drug and AI-enabled platform acquisitions. 

That capital is looking for assets to acquire, platforms to license, and operators to partner with. If your company is in the right therapeutic area, has a credible development or commercialization story, and is operationally well-run — you are a potential target. The question is whether you are visible and ready when the conversation happens.

Most growth-stage companies are not. Not because they lack the science, but because they have not done the strategic work to position themselves for this moment.

Know Your Acquirer Before They Know You

The first thing I tell growth-stage biopharma CEOs in today's environment is this: map your acquirer landscape now, not when you get an inbound call.

Who are the five to ten large pharma or specialty pharma companies most likely to acquire a company in your therapeutic area, at your stage, with your modality? What are their pipeline gaps? What patent expirations are they most exposed to? What is their M&A track record — do they integrate well or not?

Merck's pursuit of Revolution Medicines was not opportunistic. It was strategic and deliberate — driven by a specific, quantified revenue gap that Merck's board had been tracking for years. Revolution was on Merck's radar long before the Financial Times reported the USD 28–32 billion talks in January 2026. 

Understanding your likely acquirers in depth — their strategic priorities, their cultural DNA, their preferred deal structures — gives you three advantages: you can proactively build relationships before a process begins, you can shape your development and commercial strategy to align with what acquirers will value, and you will be a significantly better negotiator when the time comes.

This work takes months to do properly. Start now.

Build for Acquirability, Not Just Approvability

The default orientation of most growth-stage biopharma companies is regulatory: get the asset approved. That is necessary, but not sufficient.

Acquirability is a different standard. It means: can a large acquirer integrate your asset into their infrastructure and make the economics work? That requires clean CMC, a credible supply chain, a market access strategy that survives payer scrutiny, and an organization that can operate under new ownership without losing the key people who built it.

I have seen deals fail at late-stage diligence because of CMC issues that were known but not prioritized. I have seen term sheets retracted because the reimbursement story did not hold up under scrutiny. These are fixable problems — but only if you address them before a potential acquirer finds them first.

Conduct a rigorous self-diligence exercise at least 18 months before you expect to be in a process. Fix what you find.

Capitalize on Capability Gaps, Not Just Asset Gaps

The most important shift in biopharma M&A right now is the move from asset acquisitions to capability acquisitions. Large acquirers are not just looking for molecules — they are looking for platforms, manufacturing know-how, delivery technology, and commercial readiness that they cannot build fast enough internally. IQVIA's 2025 review confirms that buyers are prioritizing "quality, late-stage assets, and strategic focus" — meaning differentiated platforms and credible commercial potential command the largest premiums. 

If you have a novel drug delivery platform, a proprietary manufacturing process, or a commercially attractive asset — that capability has strategic value well beyond your current pipeline.

Make sure your investor materials, your corporate narrative, and your business development conversations explicitly articulate the capability, not just the asset. Many growth-stage companies bury their most strategically valuable attributes in the appendix of their pitch deck.

Raise Capital From Strategic Investors Now

The capital markets have improved, and strategic investors — corporate venture arms of large pharma, specialty pharma-focused funds, and crossover investors — are actively deploying capital into growth-stage biopharma right now.

A strategic investment is not just capital. It is a relationship, a validation signal, and often the first step in an acquisition process. Roche, AbbVie, Pfizer, and others all have active corporate venture programs specifically designed to build acquisition optionality.

If your current cap table is exclusively financial investors, consider a strategic round — not because you need the money, but because of who comes with it.

What to Avoid

Two pitfalls are particularly common for growth-stage CEOs navigating this environment.

Do not optimize for a valuation that kills the deal. The collapsed Merck/Revolution Medicines talks are a textbook example. Revolution Medicines' stock fell 22% the day the deal collapsed — wiping out much of the 47% rally that had built on acquisition speculation. A deal that closes at a fair valuation and integrates successfully creates more long-term value for founders, employees, and patients than a deal that fails over a valuation gap.

Do not wait for the perfect moment. The companies that will capture the most value from the current M&A cycle are the ones doing the strategic preparation today — not the ones who start scrambling when the inbound call arrives. With M&A spend nearly doubling in 2025 and ING forecasting further acceleration in 2026, the cycle is already well underway.

The patent cliff is reshaping the entire biopharma landscape. For growth-stage companies with the right assets, the right capabilities, and the right preparation, it represents a generational opportunity.

At Katogen, we help growth-stage biopharma CEOs navigate exactly these moments — from strategic positioning and acquirer mapping to capital raise preparation and transaction advisory — grounded in 35+ years of operator experience, 17 acquisitions, and USD 4B+ raised.